This deal adds two more siRNA candidates to GSK’s pipeline, which is expanding as the company looks to offset the impact of ...

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing ...

The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new framework to spur the development of therapies for ultra-rare ...

Beren Therapeutics has received the US (FDA acceptance to review its NDA for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset NPC.

Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.

Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) to enhance pharmaceutical education and research ...

Three new members could join Novo’s council, which largely consists of recent appointees following a restructure in October ...

The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.

J&J's Pennsylvania cell therapy manufacturing site is one of four US-based facilities the company plans to build over the ...

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

Following a difficult year that saw Ixchiq’s license suspended in the US, Valneva is pinning hopes on upcoming pipeline ...

J&J has received the US FDA approval for a new monthly dosing schedule for the combination therapy Rybrevant Faspro to treat ...